Table 3 Comparison of clinical features and outcomes by year of diagnosis, all centers combined (bilateral breast cancer subjects excluded, stage IV included).
From: An international cohort study of breast cancer survival in young women
Year of diagnosis | ||||||
|---|---|---|---|---|---|---|
1970–1995 | 1996–2000 | 2001–2005 | 2006–2010 | 2011–2015 | 2016–2020 | |
Number of patients | 4723 | 6191 | 6549 | 6261 | 6587 | 6344 |
Size (mm) | ||||||
< =20 | 2086 (50.1%) | 2748 (49.9%) | 2865 (48.1%) | 2502 (43.2%) | 2342 (38.1%) | 2191 (36.6%) |
21-50 | 1683 (40.4%) | 2276 (41.3%) | 2456 (41.2%) | 2533 (43.8%) | 2857 (46.4%) | 2820 (47.1%) |
50+ | 395 (9.5%) | 488 (8.9%) | 641 (10.8%) | 755 (13.0%) | 954 (15.5%) | 971 (16.2%) |
Missing | 559 | 679 | 587 | 471 | 434 | 362 |
Mean | 27.2 (0-300) | 26.4 (0-280) | 27.7 (0-300) | 29.5 (0-300) | 31.9 (0-300) | 32.3 (0-300) |
Node | ||||||
Negative | 2088 (52.3%) | 2800 (51.7%) | 3040 (51.0%) | 2892 (49.7%) | 3009 (48.0%) | 3155 (51.2%) |
Positive | 1908 (47.8%) | 2616 (48.3%) | 2925 (49.0%) | 2923 (50.3%) | 3254 (52.0%) | 3002 (48.8%) |
Missing | 727 | 775 | 584 | 446 | 324 | 187 |
ER | ||||||
Negative | 1603 (44.9%) | 2003 (42.0%) | 2195 (39.9%) | 1930 (34.2%) | 1809 (29.5%) | 1689 (27.6%) |
Positive | 1966 (55.1%) | 2767 (58.0%) | 3309 (60.1%) | 3714 (65.9%) | 4326 (70.5%) | 4415 (72.4%) |
Missing | 1154 | 1421 | 1045 | 617 | 452 | 244 |
HER2 | ||||||
Negative | 64 (67.4%) | 50 (79.4%) | 366 (70.1%) | 1134 (71.5%) | 4254 (71.9%) | 4385 (73.5%) |
Positive | 31 (32.6%) | 13 (20.6%) | 156 (29.9%) | 452 (28.5%) | 1665 (28.1%) | 1581 (26.5%) |
Missing | 4628 | 6128 | 6027 | 4675 | 668 | 378 |
Tamoxifen Use among ER positive pts | ||||||
No | 59 (83.1%) | 30 (35.3%) | 34 (10.8%) | 22 (10.1%) | 7 (5.0%) | * |
Yes | 11 (15.5%) | 55 (64.7%) | 281 (89.2%) | 195 (89.9%) | 132 (95.0%) | |
Missing | 1 (1.4%) | |||||
Chemotherapy | ||||||
No/Unknown | 1594 (33.8%) | 1805 (29.2%) | 1673 (25.6%) | 1472 (23.5%) | 1643 (24.9%) | 1671 (26.3%) |
Yes | 3129 (66.3%) | 4386 (70.8%) | 4876 (74.5%) | 4789 (76.5%) | 4944 (75.1%) | 4673 (73.7%) |
Radiotherapy | ||||||
No/Unknown | 2591 (54.9%) | 3128 (50.5%) | 3247 (49.6%) | 3222 (51.5%) | 3311 (50.3%) | 3161 (49.8%) |
Yes | 2132 (45.1%) | 3063 (49.5%) | 3302 (50.4%) | 3039 (48.5%) | 3276 (49.7%) | 3183 (50.2%) |
Stage 1 | 1315 (32.4%) | 1708 (31.5%) | 1764 (29.9%) | 1529 (26.6%) | 1480 (24.0%) | 1459 (24.4%) |
Stage 4 | 153 (3.8%) | 219 (4.0%) | 236 (4.0%) | 341 (5.9%) | 455 (7.4%) | 480 (8.0%) |
Survival at | ||||||
5 years | 76.7% | 79.7% | 83.2% | 83.6% | 83.5% | 84.1% |
10 years | 66.1% | 69.4% | 73.5% | 74.8% | 75.4% | NA |
